In addition, there are benefits to enhancing the complement activity of mAb-targeting bacterial cells, where studies have demonstrated that bacterial infections can be controlled by complement, but not FcγR-mediated effector mechanisms47,48. The gene discussed is FCGR2A; the disease is bacterial infectious disease.